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Aim: Recently we have observed differences in the ability of metformin and AICAR to repress
glucose production from hepatocytes using 8CPT-cAMP. Previous results indicate that, in addi-
tion to activating protein kinase A, 8CPT-modified cAMP analogues suppress the nitroben-
zylthioinosine (NBMPR)-sensitive equilibrative nucleoside transporter ENT1. We aimed to
exploit 8CPT-cAMP, 8CPT-2-Methyl-O-cAMP and NBMPR, which is highly selective for a high-
affinity binding-site on ENT1, to investigate the role of ENT1 in the liver-specific glucose-
lowering properties of AICAR and metformin.
Methods: Primary mouse hepatocytes were incubated with AICAR and metformin in combina-
tion with cAMP analogues, glucagon, forskolin and NBMPR. Hepatocyte glucose production
(HGP) and AMPK signalling were measured, and a uridine uptake assay with supporting LC-MS
was used to investigate nucleoside depletion from medium by cells.
Results: AICAR and metformin increased AMPK pathway phosphorylation and decreased HGP
induced by dibutyryl cAMP and glucagon. HGP was also induced by 8CPT-cAMP, 8CPT-
2-Methyl-O-cAMP and NBMPR; however, in each case this was resistant to suppression by
AICAR but not by metformin. Cross-validation of tracer and mass spectrometry studies indicates
that 8CPT-cAMP, 8CPT-2-Methyl-O-cAMP and NBMPR inhibited the effects of AICAR, at least
in part, by impeding its uptake into hepatocytes.
Conclusions: We report for the first time that suppression of ENT1 induces HGP. ENT1 inhibi-
tion also impedes uptake and the effects of AICAR, but not metformin, on HGP. Further investi-
gation of nucleoside transport may illuminate a better understanding of how metformin and
AICAR each regulate HGP.
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1 | INTRODUCTION
Stimuli that raise cyclic adenosine monophosphate (cAMP) levels in
hepatocytes, including glucagon, induce de novo glucose production
through gluconeogenesis and from glycogenolysis.1 Hyperglucagonae-
mia contributes to the chronic hyperglycaemia observed in type
1 (T1D) and type 2 (T2D) diabetes through poorly defined mecha-
nisms. Raised intracellular cAMP activates downstream effectors
including cAMP-dependent protein kinase (PKA)1,2 to control gluco-
neogenic flux through fructose-1,6-bisphosphatase. In addition, phos-
phorylation of cAMP-response element binding protein (CREB) by
PKA is believed to contribute to gluconeogenesis through increased
expression of phosphoenolpyruvate carboxykinase (PEPCK) and
glucose-6-phosphatase (G6-Pase).*These authors contributed equally to this work.
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The hyperglycaemic effect of the glucagon/cAMP/PKA signalling
pathway on liver cells has been studied using a number of different
cAMP analogues, in combination with dexamethasone, to stimulate
cAMP/PKA.3–5 The cAMP analogue dibutyryl cAMP (bucladesine, db-
cAMP), a cell-permeable stabilized cAMP mimic that also inhibits
phosphodiesterase (PDE) activity, is commonly used.6,7 Treatment of
cells with db-cAMP causes a significant stimulation of PEPCK and
G6-Pase expression, which is inhibited by the addition of insulin in a
dose-dependent manner.8–10 8-(4-chlorophenylthio)cAMP (8CPT-
cAMP), like db-cAMP, is a membrane-permeable cAMP analogue that
stimulates PEPCK and G-6-Pase.4,11 It tends to be more potent than
cAMP, is more resistant to phosphodiesterase-dependent hydrolysis
and acts as a PDE inhibitor.12
Studies using cAMP analogues have shown previously that the
T2D drug metformin and 5-Aminoimidazole-4-carboxamide ribonucleo-
side (AICAR) repress cAMP-stimulated hepatocyte glucose production
(HGP).13–15 Inside cells, AICAR is phosphorylated by adenosine kinase
to form ZMP, which then mimics AMP to activate AMPK.16 Metformin
and AICAR are both activators of AMPK; however, earlier studies,
including some carried out in mice where the catalytic subunits of
AMPK are genetically ablated, demonstrated that suppression of HGP
occurs independently of AMPK activation.13–15,17,18 Metformin is
transported across hepatocyte cell membranes, at least in part, by an
organic cation transporter (OCT) family of transporters.18–20 Previous
studies using siRNA determined that AICAR is transported by ENT1
and CNT3 into human macrophages,21 whereas AICAR uptake into
hepatocytes and its role concerning HGP is less clear. Initiating the cur-
rent investigation, we observed that HGP was highly resistant to inhibi-
tion by AICAR only when 8CPT-modified cAMP analogues were used
to stimulate HGP. In contrast, repression of HGP by metformin was
unaffected. 8CPT-modified cAMP analogues have been shown previ-
ously to inhibit the equilibrative nucleoside transporter (ENT1), which is
expressed in the liver22 and transports nucleosides across the plasma
membrane, depending on the nucleoside concentration gradient.23 The
inhibitory effect of 8CPT-modified cAMP analogues on AICAR action
prompted us to investigate the role of ENT1 in metformin and AICAR-
induced regulation of HGP using NBMPR, a highly selective ENT1
inhibitor.24 Our study indicates that suppression of ENT1 activity is suf-
ficient to induce HGP. Moreover, the effects of AICAR, but not of met-
formin, on HGP are sensitive to ENT1 inhibition. These data highlight
direct and indirect roles of ENT1 in modulating HGP.
2 | MATERIALS AND METHODS
2.1 | Materials
AICAR and 4-Nitrobenzylthioinosine (NBMPR) were purchased from
Tocris (Abingdon, UK). Dibutyryl cAMP, uridine and metformin were pur-
chased from Sigma (Dorset, UK). LC-MS materials were obtained from
Fisher Scientific (Loughborough, UK) unless otherwise stated. Glucagon
was obtained from Novo Nordisk (Bagsvaerd, Denmark). 8CPT-cAMP
was purchased from Calbiochem (Nottingham, UK) and 8CPT-2-Methyl-
O-cAMP (8CPT-2MeO-cAMP) was purchased from Biolog Life Sciences
Institute (Bremen, Germany). Donkey anti-goat 680RD, donkey anti-
mouse 680RD, donkey anti-rabbit 800CW secondary antibodies were
purchased from LI-COR Biosciences, UK. The GAGO glucose oxidase kit
was purchased from Sigma. [5,6-3H] uridine was purchased from Perkin
Elmer (Beaconsfield, UK). pAMPK (Thr172) and total ACC antibodies
were purchased from Cell Signalling Technologies (Leiden, UK). Total
AMPK was purchased from Abcam (Cambridge, UK) and actin was pur-
chased from Proteintech (Manchester, UK). pACC was made in-house by
Division of Signal Transduction Therapy (University of Dundee).
2.2 | Isolation of mouse primary hepatocytes
Hepatocytes were isolated from adult female mice, essentially as
described by Foretz et al.14 and in accordance with the Animals
(Scientific Procedures) Act 1986. Following successful isolation, cell
viability was determined by 0.04% Trypan blue staining and the cell
number was determined using a haemocytometer. Cell viability of
>90% was required before experimental use. Cells were plated at a
density of 2.5 × 105 cells per ml for all experiments.
2.3 | Measurement of hepatocyte glucose
production (HGP) from primary cells
HGP was measured, essentially as previously described,25 using mouse
primary hepatocytes. Viable cells were allowed to settle for 4-6 hours
before serum starvation in M199 media containing dexamethasone
(100 nM). Following overnight serum free conditions, cells were washed
once in PBS before incubation for 8 hours in glucose-free DMEM
(Invitrogen, Paisley, UK) containing lactate (10 mM), pyruvate (1 mM),
dexamethasone (100 nM) plus stimuli, as indicated in the Figure legends.
Media was harvested for measurement of glucose and hepatocytes were
lysed. The amount of glucose present in the media was measured using a
GAGO glucose oxidase kit (Sigma). Glucose assays were performed in a
96-well plate format. 50 μL of cell culture media was incubated with
100 μL of glucose oxidase/peroxidase assay reagent for 30 minutes at
37C before the reaction was stopped by addition of 100 μL 12 N
H2SO4. Absorbance was measured at 405 nm and the amount of glucose
present was determined using a glucose standard curve generated in the
same assay. The final glucose concentration was normalized to total pro-
tein content per well and data are presented as mg HGP per μg protein.
2.4 | Cell lysis and western blotting
Cells were lysed in buffer containing Tris-HCl (50 mM; pH 7.4), NaF
(50 mM), sodium pyrophosphate (1 mM), EDTA (1 mM), EGTA
(1 mM), NaCl (50 mM), sucrose (0.27 M), 1% (v/v) Triton-X100, 0.1%
(v/v) 2-mercaptoethanol, sodium orthovanadate (1 mM), benzamidine
(1 mM) and 0.1% (v/v) pefabloc, a serine protease inhibitor. Cells were
allowed to lyse on ice for 30 minutes before scraping. Lysates were
centrifuged at 13 K rpm for 15 minutes, at 4C and were prepared in
(final) 1x LDS buffer (Invitrogen) plus DTT (10 mM). Gels were run at
150 V for 90 minutes and were transferred onto nitrocellulose
(GE Healthcare, Amersham, UK) for 3 hours at 75 V before blocking in
1% (w/v) BSA, TBS-T for 30 minutes at room temperature. Mem-
branes were incubated with primary antibodies and diluted 1:1000,
with the exception of actin, which was diluted 1:5000, as indicated in
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the Figure legends, at 4C overnight, with shaking before washing
3 × 10 minutes in 1xTBS-T. Secondary antibodies (LI-COR Biosci-
ences, UK) were added at 1:5000 for 1 hour at room temperature,
with shaking. Protein bands were visualized using the LI-COR Odys-
sey infra-red imaging system.
2.5 | Uridine uptake assay
Primary mouse hepatocytes were incubated overnight in M199 media
as described above. Cells were washed once in uridine uptake buffer
(20 mM Tris-HCl, 3 mM KH2PO4, 1 mM MgCl2.6H2O, 2 mM CaCl2,
5 mM Glucose, 130 mM NaCl, pH 7.4) before incubating at room tem-
perature in 400 μL uridine uptake buffer containing DMSO (0.1%
v/v), NBMPR (100 nM), 8CPT-cAMP (100 μM), 8CPT-2MeO-cAMP
(100 μM), db-cAMP (100 μM) or glucagon (100 nM). After
15 minutes, 400 μL uridine uptake buffer containing compounds plus
0.1 μM (2 μCi/mL) 3H-uridine was added. After 1 minute, uridine
transport was stopped by washing cells five times in ice cold uridine
uptake buffer containing cold uridine (1 mM). Cells were lysed in
200 μL 10% (w/v) SDS before scraping. The amount of uridine taken
into the cell was determined by scintillation counting. Data are repre-
sented as percentage uptake compared with untreated control.
2.6 | Liquid chromatography-mass spectrometry
(LC-MS) analysis
Samples of culture media were transferred into 300 μL micro-vials and
capped (PN 60180-507 and PN 60180-516) (Thermo Scientific, Hemel
Hempstead, UK). LC-MS analysis was performed with a Thermo Accela
600 HPLC system, coupled with an Accela PDA detector (Thermo-
Fisher Ltd., Hemel Hempstead, UK). Samples were stored in the auto-
sampler at 6C and were analysed within 24 hours of preparation. The
HPLC flow rate was 300 μL/min and the column (Gemini C6-Phenol
110Ä, 150 × 2 mm, 5 μm particle size) (Phenomenex Ltd. Macclesfield,
UK) was maintained at a temperature of 30C. Solvent A was 5 mM
ammonium acetate in deionized water (ELGA-PureLab option-Q) (Elga
Ltd, High Wycombe, UK) adjusted to pH 3.5 with acetic acid and sol-
vent B was HPLC grade acetonitrile (Fisher Scientific Ltd, Loughbor-
ough, UK). Prior to sample analysis, the column was conditioned with
solvents A and B for 40 minutes. Samples (10 μL) were injected and
eluted on a gradient programme of 100% A over 0-2 minutes, 100%-
95% A over 2-5 minutes; 95%-55% A over 5-25 minutes; 55% A-100%
B over 25-26 minutes; hold 100% B over 26-29 minutes, followed by
100% B-100% A over 29-30 minutes, followed by 100% A over
30-35 minutes. HPLC needle washes were performed with 8:2
acetonitrile:water. An Accela PDA detector collected spectra from
200-600 nm and monitored channels at 280, 365 and 520 nm.
PDA detector eluent was transferred to a Thermo LTQ-Orbitrap
XL mass spectrometry system operated under Xcalibur software
(Thermo-Fisher Ltd). For the first 3 minutes, the HPLC eluent flow
was directed to waste, after which, over 3-35 minutes, it was directed
to the FT-MS detector. Mass spectra were collected in full scan mode
(m/z 80-2000) at a mass resolution of 30 000 in both positive and
negative ESI modes; however, positive mode provided the greatest
sensitivity for AICAR. A second method was employed to validate
compound identification through retention time and MS2 spectral
matching to the reference standard. Here, data-dependent MS2 CID
fragmentation spectra (acquisition-Q 0.25, activation time 25 ms, nor-
malised collision energy 10, optimized for AICAR and metformin) were
collected in the LTQ for the three most intense ions, as defined within
the preliminary full FT-MS scan. Both scan events generated “cen-
troid” spectral data. Scan speeds of 0.1 seconds and 0.4 seconds were
applied in the LTQ and FT-MS, respectively. The automatic gain con-
trol was set to 1 × 105 and 5 × 105 for the LTQ and FT-MS, respec-
tively. ESI settings were optimized to allow efficient ionization and ion
transmission with low in-source fragmentation, spray voltage +4.5 kV,
sheath gas 60, auxiliary gas 20, capillary voltage +10 V, tube lens volt-
age +80 V and capillary temperature at 280C.
The MS detector was calibrated according to the manufacturer's
instructions, after which it was tuned to optimize detection of ions in
the mid m/z 80-2000 range. All samples were run in a randomized
order, with control and blank samples interspersed at every six ana-
lyses and at the beginning and end of the run, to monitor HPLC-MS
background and target compound carryover.
A stock solution of 750 μM AICAR (99% + pure) (Sigma Chemical
Co. Ltd) was prepared in fresh culture media (Dulbecco's Modified
Eagle Medium 1X) (Gibco Life Technologies Corp., Paisley, UK), after
which it was serially diluted in culture media to provide calibration
standard curves. Extracted ion chromatograms for AICAR were gener-
ated within Xcalibur Qual Browser software; peak areas were
extracted applying the GENESIS peak detection algorithm and raw
extracted peak areas were transferred to Microsoft Excel.
2.7 | Statistics
All statistical analyses were performed using GraphPad Prism version
6.0. Mean glucose values were taken from each experiment, and in
one experiment were normalized to control, which was set at 100% to
account for variability among different hepatocyte preparations. HGP
and western blotting data were analysed by ANOVA. For the uridine
uptake assay, data were expressed as percentage of control uptake
and were analysed by one sample t-test, with control set to 100%.
3 | RESULTS
3.1 | 8CPT-cAMP inhibits AICAR, but not
metformin, repression of HGP
Primary mouse hepatocytes were serum starved overnight before
incubating with 8CPT-cAMP (100 μM), in the presence or absence of
AICAR (250 μM) or metformin (250 μM), for 8 hours. Consistent with
previous work,26 incubation of hepatocytes with 8CPT-cAMP
increased HGP. AICAR (250 μM) caused an almost complete inhibition
of basal, but not 8CPT-cAMP-stimulated HGP, suggesting that 8CPT-
cAMP interferes with the ability of AICAR to inhibit HGP. In contrast,
although metformin (250 μM) caused only a modest repression of
basal HGP, it significantly repressed 8CPT-cAMP-stimulated HGP
(Figure 1A). Metformin and AICAR both activate AMPK. Previous
work, including experiments in which AMPK activity was genetically
ablated, indicate that AMPK is not essential for regulation of HGP,
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although both drugs activate AMPK.13–15,17,18 In the current study,
we used AMPK activation purely as a marker of drug entry into the
cell. 8CPT-cAMP prevented increases in phosphorylation of acetyl
CoA carboxylase (ACC) and AMPK by AICAR, but not by metformin
(Figure 1B,D), indicating that activation of the AMPK signalling path-
way by AICAR was selectively blocked by 8CPT-cAMP.
3.2 | Inhibition of AICAR's effects depends
on the 8CPT moiety of 8CPT-cAMP
We investigated the ability of AICAR to suppress HGP in the presence
of db-cAMP and glucagon to induce endogenous cAMP. In contrast to
8CPT-cAMP, AICAR significantly repressed HGP in the presence of
db-cAMP (100 μM) (Figure 2A) and glucagon (100 nM) (Figure 2B). In
addition, the effects of AICAR on AMPK and ACC phosphorylation
were not modified by db-cAMP and glucagon (Figure 2C,E). AICAR
also suppressed HGP induced by the adenylate cyclase activator for-
skolin (100 μM) (Figure S1). To determine whether other 8CPT-
modified cAMP analogues inhibit the effect of AICAR on HGP and
AMPK signalling, we utilized 8CPT-2MeO-cAMP. We incubated pri-
mary mouse hepatocytes with 8CPT-2MeO-cAMP and found that,
similar to 8-CPT-cAMP, 8CPT-2MeO-cAMP blocked repression of
HGP by AICAR (Figure 3A). When the effects of 8CPT-2MeO-cAMP
on AMPK and ACC phosphorylation were studied, we found that, like
8CPT-cAMP, 8CPT-2MeO-cAMP selectively inhibited AICAR's, but
not metformin's ability to stimulate AMPK signalling (Figure 3B,F).
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FIGURE 1 8CPT-cAMP inhibits the ability of AICAR, but not of metformin, to suppress HGP in primary hepatocytes. A, HGP was measured from
primary mouse hepatocytes after 8 hours of incubation, with or without 8CPT-cAMP (100 μM), in the presence or absence of metformin (Met)
(250 μM) or AICAR (250 μM). B, Representative immunoblots of pThr172 AMPK and pSer79 ACC from primary hepatocytes treated with
metformin (250 μM), AICAR (250 μM)  8CPT-cAMP (100 μM). C, D Densitometric analysis of phosphorylation of ACC (C) and AMPK (D),
expressed as fold change of control (n = 3). All data are expressed as mean  SEM and were analysed by ANOVA (*P < 0.05; **P < 0.01;
***P < 0.001). Abbreviation: Con, control
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3.3 | AICAR uptake into hepatocytes is mediated
by equilibrative nucleoside transporter 1 (ENT1)
Previous studies have shown that 8-CPT-modified cAMP analogues
are potent inhibitors of the equilibrative nucleoside transporter
1 (ENT1),23 which, in brain slices, was previously found to mediate
AICAR uptake.27 This led us to test whether AICAR uptake into hepa-
tocytes may be blocked by inhibition of ENT1. We incubated primary
mouse hepatocytes with AICAR and metformin in the presence of the
selective ENT1 inhibitor NBMPR (Figure 4A). This compound was suf-
ficient to promote HGP alone, but completely blocked the action of
AICAR on HGP (Figure 4B). The effect of metformin on AMPK and
ACC phosphorylation was not modified by the presence of NBMPR
(Figure 4B,D), whereas AICAR failed to alter AMPK or ACC phosphor-
ylation in the presence of NBMPR (Figure 4B,E,F). These data strongly
suggest that AICAR uptake into mouse hepatocytes is mediated by
ENT1. To confirm that 8CPT-cAMP and 8CPT-2MeO-cAMP inhibit
ENT1 in hepatocytes, we performed an uptake assay, using radio-
labelled uridine as a tracer and a known ENT1 substrate to measure
ENT1 activity in the absence and presence of NBMPR, 8CPT-cAMP,
8CPT-2MeO-cAMP, db-cAMP and glucagon. We found that 3H-
uridine uptake was inhibited by NBMPR, 8CPT-cAMP and 8CPT-
2MeO-cAMP but was not inhibited by db-cAMP or glucagon
(Figure 5). To reinforce these findings, we carried out LC-MS analysis
of AICAR depletion from cellular medium. A scan of cell culture
medium without AICAR is presented online (Figure S2A). On the same
column, AICAR ran as a single peak at 2.91 minutes (Figure S2B-S2D).
We then established that addition of AICAR alone to the medium was
stable up to 24 hours, with LC-MS traces superimposable (0 vs
360 minutes) (Figure 5B), indicating that AICAR is not degraded over
this time-period. In contrast, in media harvested from cells treated
with AICAR, we observed AICAR loss from the medium (Figure 5C),
which was blocked by NBMPR, 8CPT-cAMP and 2MeO-8CPT-cAMP
(Figure 5D).
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FIGURE 2 Dibutyryl cAMP and glucagon do not inhibit the effect of AICAR on HGP or AMPK signalling. Primary mouse hepatocytes were
incubated for 8 hours with either dibutyryl cAMP (db-cAMP, 100 μM) A, or glucagon (100 nM) B, in the presence or absence of metformin (Met)
(250 μM) or AICAR (250 μM). The amount of glucose produced was measured as in Figure 1A. C, Immunoblots showing pT172 AMPK and pS79
ACC phosphorylation in response to db-cAMP (100 μM). D, E, Densitometric analysis of phosphorylation of ACC (D) and AMPK (E), expressed as
fold change of control. Data are expressed as mean  SEM from three separate experiments and were analysed by ANOVA (*P < 0.05;
**P < 0.01; ***P < 0.001 in post hoc comparisons). Abbreviation: Con, control
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FIGURE 3 Suppression of HGP and AMPK signalling by AICAR is inhibited by the 8CPT-modified cAMP analogue 8CPT-2-methyl-O-cAMP.
Primary hepatocytes were treated for 8 hours with metformin (Met) (250 μM) or AICAR (250 μM)  8CPT-2MeO-cAMP (100 μM) A, Media
were harvested and HGP was measured as in Figure 1A (n = 4). B, Representative immunoblots of pThr172 AMPK and pSer79 ACC
phosphorylation in lysates treated with metformin (Met) (250 μM) or AICAR (250 μM)  8CPT-2MeO-cAMP (100 μM). C-F, Densitometric
analysis of ACC (C, E) and AMPK (D, F) phosphorylation, expressed as fold change of control (n = 4). Data are expressed as mean  SEM and
were analysed by ANOVA (*P < 0.05; **P < 0.01; ***P < 0.001 in pairwise comparisons). Abbreviation: Con, control
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4 | DISCUSSION
Regulation of HGP is key to maintaining adequate blood glucose
control in T1 and T2 diabetes. Glucagon and a number of cAMP
analogues, including 8CPT-cAMP and db-cAMP, are used in pre-
clinical studies to mimic HGP in the fasted state, allowing the liver-
specific effects of metformin and AICAR on HGP to be studied
in vitro. This study was prompted by our observation that 8CPT-
cAMP selectively blocks suppression of HGP and activation of
AMPK signalling in response to AICAR, but not in response to met-
formin. Db-cAMP and glucagon stimulated HGP, which was
reversed by AICAR. A second 8CPT-modified analogue, 8CPT-
2MeO-cAMP produced a similar selective block of the effect of
AICAR on both HGP and AMPK signalling. Earlier investigations
found that 8CPT-cAMP and 8CPT-adenosine did not inhibit the
binding of [3H]NBMPR to PC12 cells23 and consequently, the
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***
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FIGURE 4 AICAR uptake into hepatocytes is mediated by equilibrative nucleoside transporter 1 (ENT1). A, HGP was measured after incubation
for 8 hours with the selective ENT1 inhibitor NBMPR (100 nM)  metformin (250 μM) or AICAR (250 μM). The amount of glucose produced
was normalized to protein content and expressed as % control. B, Representative immunoblots measuring pThr172 AMPK and pSer79 ACC by
metformin (250 μM) or AICAR (250 μM)  NBMPR (100 nM). C-F, Densitometric analysis of ACC (C, E) and AMPK (D, F) phosphorylation,
expressed as fold change of control. Data are taken from 4 separate experiments and shown as mean  SEM, (*P < 0.05; **P < 0.01;
***P < 0.001 in pairwise comparisons). Abbreviations: Con, control; ns, not significant
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mechanism of 8CPT-cAMP/8CPT-adenosine dependent inhibition of
ENT1 is uncertain but is probably related to the fact that 8CPT-
cAMP is more lipophilic than cAMP by one order of magnitude.28
This significant off-target effect of 8CPT-modified cAMP analogues
suggests that caution should be exercised in future studies using
8CPT-cAMP to stimulate HGP. In the current study, however, we
FIGURE 5 Legend on next page.
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exploited this action of 8CPT-modified cAMP analogues to compare
hepatic actions of AICAR and metformin.
We excluded a role for PKA/Epac activation in the blocking effect
of 8CPT-modified cAMP analogues on AICAR-dependent suppression
of HGP, on the assumption that cAMP does not affect the inhibitory
effect of AICAR on HGP, when raised by the physiological inducer of
cAMP, glucagon, and by the adenylate cyclase activator, forskolin.
Importantly, it has been reported previously that 8CPT-modified
cAMP analogues inhibit nucleoside transporters,23 which are divided
into two different families: constitutive nucleoside transporters (CNT)
(SLC28), of which there are three members (CNT1-3) or equilibrative
nucleoside transporters (ENT) (SLC29), of which there are four mem-
bers (ENT1-4).29 These nucleoside transporters are responsible for
transporting nucleosides such as adenosine and uridine into the cell.
In the brain, AICAR elevates adenosine levels, thought to be mediated
by competition for or blockade of ENT1.27 Therefore, we used a
highly selective inhibitor of ENT1, NBMPR, to demonstrate that ENT1
inhibition is sufficient to block the effect of AICAR on HGP and AMPK
signalling. Molecular docking data are unavailable for 8CPT-cAMP
analogues docking to ENT1 but in contrast, robust 3D-Quantitative
Structure-Activity Relationship analysis is available for NBMPR/ENT1
interaction.30–32 NBMPR did not alter the effects of metformin on
AMPK and HGP. At the nanomolar concentrations used in the current
study, NBMPR is highly specific for ENT1 which has a unique high-
affinity binding site for this drug.24 In recombinant systems, NBMPR
inhibits ENT1 7000-fold more potently than ENT2,24,33 and it does
not inhibit CNT3.34 In rat hepatic membrane preparations, NBMPR is
without effect on Na+-dependent (concentrative) adenosine transport
activity.35 To further validate that AICAR was taken up via ENT1, we
used 3H-uridine as a tracer. We confirmed that 8CPT-cAMP ana-
logues and NBMPR inhibit uridine uptake into hepatocytes. We then
cross-validated with LC-MS, demonstrating that AICAR is depleted
from media harvested from AICAR-treated hepatocytes, which was
prevented by NBMPR and 8CPT-modified cAMP analogues. Using an
additional control, we did not observe any major degradation products
of AICAR in the medium, indicating that AICAR depletion is most likely
the result of cellular uptake. The difference between AICAR and met-
formin sensitivity to NBMPR is consistent with metformin being taken
into the cell via OCT transporters, as reported previously.19,20 Our
findings may explain previous observations that required the use of
very high (2 mM) concentrations of AICAR to inhibit 8CPT-cAMP-
induced HGP.11 Taken together, our data suggest that 8CPT-modified
cAMP analogues and NBMPR inhibit ENT1 to block AICAR entry, pre-
venting AICAR-mediated inhibition of HGP and activation of AMPK
(Figure 5E).
Direct ENT1 inhibition with NBMPR which, in other tissues, raises
extracellular adenosine levels,36,37 was sufficient to increase HGP
(Figure 5E). This is probably mediated indirectly by activation of aden-
osine receptor-mediated glycogenolysis or gluconeogenesis.38 In addi-
tion to adenosine, ENT1 also transports uridine, which promotes
feeding via activation of hypothalamic uridine diphosphate receptor,
P2Y6,39 and which may also contribute AMPK-independent effects of
AICAR on metabolism. Several clinically used drugs inhibit ENT1 as a
secondary mode of action, including rosuvastatin40 and dipyrida-
mole.41 Interestingly, rosuvastatin increases HbA1c in individuals with
and without diabetes,42 and dipyridamole increases glycaemia in
mice.43 Taken together, these data suggest that therapeutic alter-
ations in purine salvage may produce a clinically significant alteration
in HGP via modulation of adenosine receptors.
In summary, we report for the first time that suppression of ENT1
induces HGP. ENT1 inhibition also impedes uptake and the effects of
AICAR, but not of metformin, on HGP. These data delineate the dif-
fering pathways by which AICAR and metformin regulate HGP, and
more study is required to determine whether exploitation of these
pathways can be used for further therapeutic intervention in diabetes.
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FIGURE 5 Nucleoside transport via equilibrative nucleoside transporter 1 (ENT1) is inhibited by 8CPT-modified cAMP analogues. Uridine uptake
into hepatocytes was measured using 3H-uridine uptake assay. Hepatocytes were incubated for 15 minutes with NBMPR (100 nM), 8CPT-cAMP
(100 μM), dibutyryl cAMP (100 μM), glucagon (100 nM) or 8CPT-2MeO-cAMP (100 μM) before measuring 3H transport into the cell for
1 minute. Data are expressed as mean  SEM and are represented as % uridine uptake relative to control (n = 3) **P < 0.01, ***P < 0.001). B,
LC-MS analysis of AICAR in medium without cells at 0 and 6 hours of incubation. The top two traces show the similarity between total MS signal
at 0 and 6 hours of incubation. The bottom two traces show the signal at the selected m/z 259 for AICAR and demonstrate that AICAR is stable
under these conditions. The full-scale deflection of the MS detector is given in the top right corner of each trace. C, AICAR disappearance from
medium in the presence of primary hepatocytes. AICAR in media was measured by LC-MS and expressed as μM AICAR. Data are expressed as
mean  SEM and were analysed by ANOVA (*P < 0.05 in pairwise comparisons). D, Effect of NBMPR, 8CPT-cAMP and 2MeO-8CPT-cAMP on
AICAR disappearance from the medium. AICAR in media was measured by LC-MS and expressed as peak areas in MS detector units. Data are
expressed as mean  SEM and analysed by ANOVA (*P < 0.05 and **P < 0.01 in pairwise comparisons). E, Schematic representation of AICAR
and metformin entry into hepatocytes and consequences of equilibrative nucleoside transporter (ENT1) inhibition. Upper section: AICAR enters
the hepatocyte through ENT1, where it is converted to AICAR monophosphate (ZMP), resulting in suppression of HGP through AMPK-
independent targets; metformin enters hepatocytes, at least in part, through organic cationic transporters (OCT) and inhibits HGP through
mechanisms including mitochondrial inhibition, affecting adenine nucleotide levels/ratios. Lower section: NBMPR inhibits adenosine uptake into
hepatocytes through ENT1, raising HGP which is possibly mediated, at least in part, by an adenosine receptor (Adora)-mediated process.
Abbreviations: Con, control; NS, not significant
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